

**Supplement Table 1.** The baseline clinical characteristics and sequential echocardiographic parameters in regard to renal function in patients with ST elevation myocardial infarction (STEMI) (N=126)

	Group 1 (<30 mL/min/1.73m) N=29	Group 2 (30-60 mL/min/1.73m) N=59	Group 3 (60-90 mL/min/1.73m) N=28	Group 4 (>90 mL/min/1.73m) N=10	P-value
Age	76.5±11.4 <sup>b,c</sup>	69±0.9 <sup>b,c</sup>	57.8±11.1 <sup>d</sup>	47.1±9.82 <sup>d</sup>	0.001
Gender (Male)	15 (51.7) <sup>a,b,c</sup>	51 (86.4) <sup>d</sup>	26 (92.8) <sup>d</sup>	8 (80) <sup>d</sup>	<0.001
BMI	23.1±3.67 <sup>c</sup>	23.5±3.5 <sup>c</sup>	26.1±3.25 <sup>c</sup>	34.8±3.5 <sup>a,b,d</sup>	0.001
<b>Cardiovascular risk factors</b>					
Diabetes	18 (62.1) <sup>a,b</sup>	14 (23.7) <sup>d</sup>	7 (25) <sup>d</sup>	4 (40) <sup>d</sup>	0.003
Hypertension	22 (75.8) <sup>b,c</sup>	35 (59.3)	13 (46.4)	3 (30) <sup>d</sup>	0.03
Hyperlipidemia	19 (65.5)	50 (84.7)	25 (89.2)	10 (100)	0.12
Smoking	11 (37.9)	27 (45.7)	12 (42.8)	4 (40)	0.19
<b>PCI for</b>					
LAD	24 (82.7) <sup>a,b,c</sup>	32 (54.2) <sup>d</sup>	14 (50) <sup>d</sup>	4 (40) <sup>d</sup>	0.02
LCX	7 (24.1)	23 (38.9)	7 (25)	1 (10)	0.17
RCA	15 (51.7) <sup>c</sup>	25 (42.4) <sup>c</sup>	12 (42.8) <sup>c</sup>	9 (90) <sup>a,b,d</sup>	0.04
One-vessel-disease	16 (55.2) <sup>b,c</sup>	39 (66.1)	23 (82.1) <sup>d</sup>	7 (70) <sup>d</sup>	0.04
Two-vessel-disease	9 (31)	19 (32.2)	5 (17.8)	2 (20)	0.78
Three-vessel-disease	4 (13.7)	1 (1.69)	0	1 (10)	0.87
<b>Drugs before discharge</b>					
Anti-platelet agents	27 (93.1)	59 (100)	28 (100)	10 (100)	0.07
Statin	14 (48.3) <sup>a,b,c</sup>	46 (77.9) <sup>d</sup>	24 (85.7) <sup>d</sup>	10 (100) <sup>d</sup>	0.001
ACEIs/ARBs	24 (82.7)	51 (86.4)	27 (96.4)	9 (90)	0.42
β-blockers	13 (44.8)	39 (66.1)	20 (71.4)	6 (60)	0.16
<b>Echocardiographic parameters</b>					
<b>Post MI (during hospitalization)</b>					
LVEF (%)	49.2±38.3 <sup>a,b,c</sup>	62.5±14.3 <sup>d</sup>	65.9±12.2 <sup>d</sup>	64.3±7.7 <sup>d</sup>	0.018
LVEDVi (ml/M2)	103±40.5 <sup>b,c</sup>	95.1±37	78.7±27 <sup>d</sup>	73.1±22 <sup>d</sup>	0.001
LVESVi (ml/M2)	49.3±27.5 <sup>b,c</sup>	38±26.56 <sup>d</sup>	27.3±15.2 <sup>d</sup>	26.3±10.73 <sup>d</sup>	0.001
LVMi (g/M2)	161.3±84.4 <sup>b,c</sup>	150.6±67 <sup>d</sup>	130.8±42.2 <sup>d</sup>	128.7±44.8 <sup>d</sup>	0.001
E/A	1.1±0.6	1.1±0.5	1.1±0.6	1±0.4	0.99
E/e'	13.7±7.9	13.5±5.4	12.2±5.1	13.4±5.1	0.76
<b>Post MI (after one year)</b>					
LVEF (%)	52.1±15.1 <sup>a,b,c</sup>	64.7±13.8 <sup>d</sup>	65.1±14 <sup>d</sup>	68.4±11.7 <sup>d</sup>	0.012
LVEDVi (ml/M2)	100.9±43.6	92.9±38.6	79.1±28.9	71±14.8	0.05
LVESVi (ml/M2)	40.7±27.1	34.9±25.8	28.4±18.5	22.5±13.4	0.18
LVMi (g/M2)	137.4±91.2	135.6±68.4	135.2±47.7	126.9±54	0.45
E/A	0.9±0.5	1.1±1.2	0.9±0.3	0.6±0.3	0.73
E/e'	15.3±6.8	12.1±4.7	13.3±6.6	12.3±5	0.12

Change of LVEF (%)	5.9±29.4	2.1±13.8	-0.7±10.9	4.1±10	0.29
Change of LVMI (g/M2)	-23.8±83.1	-14.9±59.5	-4.3±52.6	-1.7±75.8	0.14
<b>Outcomes</b>					
Cardiovascular death	2	0	0	0	0.07
Hear failure	8	6	3	0	0.05
Ventricular arrhythmia (VT/VF)	1	1	0	0	0.63
Recurrent myocardial infarction (MI)	5	6	2	2	0.5
Revascularization	8	13	7	3	0.92

<sup>a</sup>*P* <0.05, compared with Group2; <sup>b</sup>*P* <0.05, compared with Group3; <sup>c</sup>*P* <0.05, compared with Group 4; <sup>d</sup>*P* <0.05, compared with Group 1  
Abbreviations as listed in Table 1